Jesper Gromada, Ph.D.
Jesper brings 25 years of experience in drug development. Prior to joining Third Rock, Jesper served as Chief Scientific Officer at Exonics Therapeutics (acquired by Vertex Pharmaceuticals) and Laronde Therapeutics. Previously, Jesper held positions of increasing responsibility at Regeneron, Novartis, Eli Lilly and Novo Nordisk. Jesper earned his Ph.D. at the University of Copenhagen, Denmark. He has contributed to the development of several clinical-stage drug candidates and marketed drugs. Jesper has published over 200 research papers and patents.
Jesper is interested in combining discoveries in biology and technology for company creation and drug development. He is impressed with the culture at Third Rock and the approach for build of innovative companies with proven abilities to develop impactful medicines.